This is an investigational study. Bortezomib and rituximab are FDA approved and commercially available. Their use in this study, however, is investigational since it is used with transplantation. All other chemotherapy drugs are FDA approved and commercially available. Up to 52 patients will take part in this study. All will be enrolled at MD Anderson.